{"url_path":"/sec/vbio/8-k/2026-07-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001683168-26-005497-index.html","accession_number":"0001683168-26-005497","cik":"0001787740","ticker":"VBIO","issuer_name":"Valion Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1787740/0001683168-26-005497-index.html","primary_entity_key":"0001787740","primary_entity_name":"Valion Bio, Inc."},"word_count":300,"has_tables":true,"body_markdown":"**Item 9.01.  Financial Statements and Exhibits.**\n\n** **\n\n**(d)  Exhibits.**\n\n** **\n\n**Exhibit No.**\n**Description**\n\n99.1\n\n[Press release of Valion Bio, Inc., dated July 14, 2026](valion_ex9901.htm)\n\n104\nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n**Forward-Looking Statements**\n\n \n\nThis Current Report, including Exhibit 99.1 attached\nhereto, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms \"anticipates,”\n\"expects,” \"estimates,” \"believes,” \"will” and similar expressions, as they relate to us or\nour management, are intended to identify such forward-looking statements.\n\n \n\nForward-looking statements in this Current Report,\nincluding Exhibit 99.1 attached hereto, or hereafter, including in other publicly available documents filed with the Securities and Exchange\nCommission, reports to the stockholders of the Company and other publicly available statements issued or released by us involve known\nand unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements\nto differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements.\nSuch future results are based upon management’s best estimates based upon current conditions and the most recent results of operations.\nThese risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange\nCommission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our\nactual results, performance or achievements may differ materially and adversely from those expressed or implied by such forward-looking\nstatements.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 2 \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n  \n\n \n \n \n**VALION BIO, INC.**\n\n \n \n \n \n\n \n \n \n \n\nDate:\nJuly 14, 2026\nBy:\n/s/ Melinda Lackey\n\n \n \n \nName: Melinda Lackey\n\nTitle: General Counsel, SVP Legal Affairs\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n 3"}